Hypothyroidism in Long-Term Care: The Pharmacist's Role | YARAL Pharma
This podcast is sponsored by YARAL Pharma. In this episode, we are focusing on the management of hypothyroidism -- a treatable, but not curable condition – and will explore unique challenges for patients with hypothyroidism in long-term care – from tolerability and formulation considerations to consistent dosing and patient needs. Dr. Tamara Ruggles is not affiliated with YARAL Pharma. All views and opinions regarding hypothyroidism are solely her own and are not attributable to YARAL or the Pharmacy Podcast Network. IMPORTANT SAFETY INFORMATION for levothyroxine sodium capsules INDICATION AND USAGE Levothyroxine sodium capsules are L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with:
- Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
- Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer
- Levothyroxine sodium capsules are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine sodium capsules may induce hyperthyroidism.
- Levothyroxine sodium capsules are not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis
- Uncorrected adrenal insufficiency
- Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease:
- Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma
- Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium capsules treatment
- Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism
- Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy
- Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone reabsorption and decrease bone mineral density. Give the lowest effective dose
- General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
- Central Nervous System: headache, hyperactivity, nervousness, anxiety, irritability, emotional ability, insomnia
- Musculoskeletal: tremors, muscle weakness
- Cardiovascular: palpitations, tachycardia, arrythmias,...
You May Also Like

Israel Today: Ongoing War Report
Israel Today: Ongoing War Report

Good Morning Liberty
Good Morning Liberty

The Jacksonville Jaguars Official Podcast Network
Jacksonville Jaguars

Global News Today | 2 Min News | The Daily News Now!
The Daily News Now!

مجلههای زنده رادیو فردا
رادیوفردا

700 WLW On-Demand
WLW-AM (WLWAM)

The Pete Quiñones Show
Peter R Quiñones

The Epstein Chronicles
Bobby Capucci

Le journal d'Europe 1
Europe 1

28 Minutes
ARTE Radio
Community discussion